Qiagen N.V.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| QIA.F | 300244.SZ | BIM.PA | 300463.SZ | ILMN | 603127.SS | |
|---|---|---|---|---|---|---|
| Market cap | 9.35B | 13.78B | 11.14B | 5.55B | 34.25B | 34.88B |
| P/E (TTM) | 26.8 | 28.6 | 24.3 | — | 39.0 | 30.4 |
| Forward P/E | 19.7 | 31.3 | 20.1 | 10.6 | 36.6 | 105.8 |
| Price/book | 3.1 | 2.0 | 2.6 | 0.9 | 10.9 | 3.7 |
| Dividend yield | 0.68% | 1.69% | 1.00% | — | — | 0.27% |
| 1-year change | +12.92% | +26.44% | −12.59% | −23.74% | +87.05% | +32.91% |
| Today | +1.00% | +6.73% | −3.07% | +1.32% | −4.90% | +5.56% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All QIA.F news ›PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
TradingView PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR
TradingView PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR
U.S. Sepsis Diagnostic Market QIAGEN Secures FDA Clearance for Rapid Bloodstream Infection Panel, Expanding Pathogen and Antimicrobial Resistance Testing
Press release - DataM Intelligence 4 Market Research LLP - U.S. Sepsis Diagnostic Market QIAGEN Secures FDA Clearance for Rapid Bloodstream Infection Panel, Expanding Pathogen and Antimicrobial Resistance Testing - published on openPR.com…
Citigroup Forecasts Strong Price Appreciation for Qiagen (NYSE:QGEN) Stock
Qiagen (NYSE:QGEN - Get Free Report) had its target price increased by research analysts at Citigroup from $45.00 to $52.00 in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage presently has a "hold"…
Maryland, Virginia Life Sciences News: QIAGEN $12.1 Billion Takeover, LUNGevity Launches Multi-Year Research & More
That push toward commercialization is also reflected in the region’s clinical progress. MacroGenics reported encouraging Phase 2 results in gynecologic cancer, while Vanda Pharmaceuticals announced positive Phase 3 results for NEREUS.…
Analyst recommendations: Boeing, Qiagen, Spotify, Applovin, Fedex…
Every morning, find a selection of analysts' recommendations covering North America. The list only includes companies that have received a rating or price target change, or new analyst coverage. It... -October 28, 2026 at 07:13 am EDT -…
Vinson & Elkins Represents Perella Weinberg Partners as Financial Advisor in EQT Takeover of Qiagen
October 22, 2026 • 1-minute read Vinson & Elkins is representing Perella Weinberg Partners as financial advisor to the Supervisory Board of Qiagen N.V. in connection with its proposed all-cash takeover offer by EQT Private Equity with a…
EQT to buy diagnostics player Qiagen for €9.6bn
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience…
Qiagen (QGEN) Expected to Post Quarterly Earnings on Wednesday
Posted by Michael Walen on Oct 28th, 2026 NYSE:QGEN opened at $50.20 on Wednesday. Qiagen has a 12 month low of $32.53 and a 12 month high of $57.81. The firm has a fifty day simple moving average of $44.73 and a 200-day simple moving…
Qiagen (NYSE:QGEN) Stock Gets Downgrade from Barclays
Qiagen (NYSE:QGEN – Get Free Report) was downgraded by equities researchers at Barclays from an “overweight” rating to an “equal weight” rating in a research note issued on Wednesday, Benzinga reports. They presently have a $53.00 price…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com29
- tradingview.com19
- marketbeat.com6
- themarketsdaily.com4
- gurufocus.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 92 articles, not a forecast.